Yintoni uvavanyo lwe-coagulation ye-PT kunye ne-INR?


Umbhali: Ophumeleleyo   

I-Coagulation INR ikwabizwa ngokuba yi-PT-INR ngokwezonyango, i-PT lixesha le-prothrombin, kwaye i-INR ngumlinganiselo oqhelekileyo wamazwe ngamazwe.I-PT-INR yinto yovavanyo lwebhubhoratri kunye nesinye sezibonakaliso zokuvavanya umsebenzi we-blood coagulation, onexabiso elibalulekileyo lokubhekisela ekusebenzeni kweklinikhi.

Uluhlu oluqhelekileyo lwe-PT yi-11s-15s kubantu abadala, kunye ne-2s-3s kwiintsana ezisanda kuzalwa.Uluhlu oluqhelekileyo lwe-PT-INR kubantu abadala ngu-0.8-1.3.Ukuba izidakamizwa ze-anticoagulant, ezifana neepilisi ze-sodium warfarin, zisetyenzisiwe, uluhlu lwe-PT-INR lunconywa ukuba lulawulwe kwi-2.0-3.0 ukufezekisa umphumo osebenzayo we-anticoagulant.Amacwecwe e-sodium ye-Warfarin asetyenziswa ngokuqhelekileyo kwii-anticoagulants zeklinikhi kunyango lwe-vein thrombosis okanye isifo se-thrombotic esibangelwa yi-fibrillation ye-atrial, isifo se-valvular, i-pulmonary embolism, njl. kwakhona isiseko oogqirha ukulungelelanisa ithamo warfarin tablets sodium.Ukuba i-PT-INR iphezulu kakhulu, ibonisa ingozi yokopha.Ukuba inqanaba le-PT-INR liphantsi kakhulu, lingabonisa umngcipheko wegazi.

Xa uvavanya i-PT-INR, ngokuqhelekileyo kuyimfuneko ukuthatha igazi le-venous.Le ndlela ayinayo imfuneko ecacileyo yokuzila ukutya, kwaye izigulane azidingi ukukhathalela ukuba zingatya okanye zingadli.Emva kokutsalwa kwegazi, kuyacetyiswa ukuba kusetyenziswe i-swab yomqhaphu engasebenziyo ukumisa ukopha, ukuze uthintele amanqanaba aphezulu e-PT-INR, ukuqina okungahambi kakuhle kuya kubangela ukugruzuka okungaphantsi kwesikhumba.

I-Beijing SUCCEEDER njengenye yeebrendi eziphambili kwimarike ye-China Diagnostic ye-Thrombosis kunye ne-Hemostasis, i-SUCCEEDER inamava amaqela e-R&D, uVeliso, uThengiso lweNtengiso kunye noBonelelo lweNkonzo abahlalutyi be-coagulation kunye ne-reagents, abahlalutyi begazi le-rheology, i-ESR kunye nabahlalutyi be-HCT, iplatelet.
abahlalutyi aggregation kunye ISO13485, CE Certification kunye FDA zidweliswe.